Orient Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Orientbio breeds and supplies laboratory animals, purpose-raised mice, rats, and other species used in drug safety and efficacy testing, along with related research services such as pharmacokinetic studies and preclinical contract research.
Its customers are pharmaceutical companies, biotech firms, and research institutions that need certified animal models before advancing a drug candidate to human trials. The company is listed on KOSPI, South Korea's main stock exchange, and operates facilities designed to keep animals free from external contamination, meeting the good laboratory practice standards required for regulatory submissions.
Summary is AI-generated and may contain errors · figures from DART filings
Orient Bio in five facts
What does Orient Bio do?
Orientbio breeds and supplies laboratory animals, purpose-raised mice, rats, and other species used in drug safety and efficacy testing, along with related research services such as pharmacokinetic studies and preclinical contract research.
Where is Orient Bio listed and in which sector?
Orient Bio (Korean name: 오리엔트바이오) trades under KRX code 002630 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Orient Bio?
Its market capitalisation was US$32.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Orient Bio's latest annual revenue and operating profit?
For fiscal year 2025, Orient Bio reported revenue of US$22.2M, an operating loss of US$2.3M and a net loss of US$10M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 5.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersSep 17
- Report on securities held by executives/major shareholdersSep 17
- Report on securities held by executives/major shareholdersSep 17
- Report on large shareholdings (5% rule) (standard)Sep 4
- Report on securities held by executives/major shareholdersSep 4
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Orient Bio updated its previously filed separate results for the fiscal year ended Mar 2026: revenue of US$19.4M (+1.2% year on year), an operating loss of US$2.69M and a net loss of US$2.97M.
Earnings · Jun 19 · 2 versions